Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Rectal endocrine intermediate-cell carcinoma].

Dominique Béchade1, Jérôme Desramé, Olivier Berthelet

  • 1Service de Clinique Médicale, Hospital du Val-de-Grace, Paris, Cedex, France. bechade.dominique@wanadoo.fr

Annales De Medecine Interne
|September 10, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France).

EClinicalMedicine·2026
Same author

STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.

Signal transduction and targeted therapy·2026
Same author

Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

EUS appearance of a rare mesenchymal tumor: Plexiform fibromyxoma.

Endoscopic ultrasound·2026
Same author

Corrigendum to 'Impact on survival without chemotherapy of local treatments of lung metastasis of colorectal cancers: Analysis on REPULCO cohort' [Digestive and Liver Disease 56 (2024) 1930-7].

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2025
Same author

Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study.

The oncologist·2025
Same journal

[Consensus Development Conference on Thrombosis and Pregnancy. 14 March 2003, Paris, France. Proceedings].

Annales de medecine interne·2004
Same journal

Kartagener's syndrome and renal failure.

Annales de medecine interne·2004
Same journal

Inflammatory pseudotumor of lymph nodes.

Annales de medecine interne·2004
Same journal

[Necrolytic migratory erythema revealing glucagonoma without diabetes].

Annales de medecine interne·2004
Same journal

[Bilateral primary non-Hodgkin's lymphomas of the adrenals].

Annales de medecine interne·2004
Same journal

[Acute "pseudo-angiocholitis" due to colonic adenocarcinoma in a man with primary sclerosis cholangitis and ulcerative colitis].

Annales de medecine interne·2004
See all related articles

A rare rectal endocrine carcinoma with specific cell markers caused diarrhea in an 82-year-old. Despite brief treatment response, the aggressive tumor rapidly metastasized, highlighting poor prognosis for gastrointestinal endocrine neoplasms.

Area of Science:

  • Gastroenterology
  • Oncology
  • Pathology

Background:

  • Rectal endocrine intermediate-cell carcinomas are rare gastrointestinal tumors.
  • These neoplasms are characterized by specific cellular markers and often present with poor prognosis.

Observation:

  • An 82-year-old patient presented with diarrhea attributed to a rectal endocrine intermediate-cell carcinoma.
  • Histological examination revealed a tumor immunoreactive for neuron-specific enolase and CD56.

Findings:

  • The tumor exhibited rapid hepatic metastasis.
  • Initial response to radiotherapy and chemotherapy was transient, indicating aggressive tumor behavior.

Implications:

  • This case underscores the challenges in managing rare gastrointestinal endocrine tumors.

Related Experiment Videos

  • Understanding recent classifications is crucial for improved diagnosis and treatment strategies for these rare, aggressive neoplasms.